Peptides as therapeutic agents or drug leads for autoimmune, hormone dependent and cardiovascular diseases

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 7, Issue 4, 2008, Pages 294-306

  Mantzourani, Efthimia ^a   Laimou, Despoina ^a   Matsoukas, Minos Timotheos ^a   Tselios, Theodore ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Altered peptide ligands (APLs); Angiotensin; Cyclic peptide; Gonadotropin releasing hormone (GnRH); Hypertension; Immunotherapy; Multiple sclerosis (MS); Peptides

Indexed keywords

ABARELIX; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA INTERFERON; BETA1A INTERFERON; BUSERELIN; CETRORELIX; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALKIREN; FINGOLIMOD; GANIRELIX; GLATIRAMER; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; IMMUNOGLOBULIN M ANTIBODY; INTERFERON BETA SERINE; LEUPRORELIN; LOSARTAN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[85-99]; NATALIZUMAB; PEPTIDE DERIVATIVE; PLACEBO; RECOMBINANT IMMUNOGLOBULIN M 22; REMIKIREN; RENIN INHIBITOR; SARALASIN; TEVERELIX; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CELL SURFACE; CLINICAL TRIAL; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENDOCRINE DISEASE; GYNECOLOGIC DISEASE; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOTHERAPY; IN VITRO STUDY; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROTRANSMISSION; NONHUMAN; PEPTIDE ANALYSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

EID: 60149091671     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152308786847799     Document Type: Article

References (145)

1. Illes, Z.; Stern, J.N.H.; Reddy, J.; Waldner, H.; Mycko, M.P.; Brosnan, C.F.; Ellmerich, S.; Altmann, D.M.; Santambrogio, L.; Strominger, J.L.; Kuchroo, V.K. Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proc. Natl. Acad. Sci. USA, 2004, 101, 11749-11754.
2. Steinman, L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron, 1999, 24, 511-514.
3. Chen, M.; Gran, B.; Costello, K.; Johnson, K.; Martin, R.; Dhib-Jalbut, S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler., 2001, 7, 209-219.
4. Neuhaus, O.; Farina, C.; Wekerle, H.; Hohlfeld, R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology, 2001, 56, 702-708.
5. Fridkis-Hareli, M.; Teitelbaum, D.; Gurevich, E.; Pecht, I.; Brautbar, C.; Kwon, O.J.; Brenner, T.; Arnon, R.; Sela, M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc. Natl. Acad. Sci. U S A, 1994, 91, 4872-4876.
6. Ziemssen, T.; Kumpfel, T.; Klinkert, W.E.; Neuhaus, O.; Hohlfeld, R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain, 2002, 125, 2381-2391.
7. Aharoni, R.; Teitelbaum, D.; Arnon, R.; Sela, M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. USA, 1999, 96, 634-639.
8. Fridkis-Hareli, M.; Santambrogio, L.; Stern, J.N.; Fugger, L.; Brosnan, C.; Strominger, J.L. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J. Clin. Invest., 2002, 109, 1635-1643.
9. Comi, G.; Filippi, M.; Wolinsky, J.S.; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol., 2001, 49, 290-297.
10. Filippi, M.; Rovaris, M.; Rocca, M.A.; Sormani, M.P.; Wolinsky, J.S.; Comi, G; European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology, 2001, 57, 731-733.
11. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L.W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995, 45, 1268-1276.
12. Filippi, M.; Wolinsky, J.S.; Comi, G.; CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Neurol., 2006, 5, 213-220.
13. Wolinsky, J.S.; Narayana, P.A.; O'Connor, P.; Coyle, P.K.; Ford, C.; Johnson, K.; Miller, A.; Pardo, L.; Kadosh, S.; Ladkani, D.; PROMiSE Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol., 2007, 61, 14-24.
14. Poser, C.M.; Paty, D.W.; Scheinberg, L.; McDonald, W.I.; Davis, F.A.; Ebers, G.C.; Johnson, K.P.; Sibley, W.A.; Silberberg, D.H.; Tourtellotte, W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol., 1983, 13, 227-231.
15. Comi, G.; Filippi, M.; Barkhof, F.; Durelli, L.; Edan, G.; Fernández, O.; Hartung, H.; Seeldrayers, P.; Sørensen, P.S.; Rovaris, M.; Martinelli, V.; Hommes, O.R.; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, 2001, 357, 1576-1582.
16. Jacobs, L.D.; Beck, R.W.; Simon, J.H.; Kinkel, R.P.; Brown-scheidle, C.M.; Murray, T.J.; Simonian, N.A.; Slasor, P.J.; Sandrock, A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med., 2000, 343, 898-904.
17. Panitch, H.; Miller, A.; Paty, D.; Weinshenker, B.; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology, 2004, 63, 1788-1795.
18. Evavold, B.D., Allen, P.M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science, 1991, 252, 1308-1310.
19. Sloan-Lancaster, J.; Shaw, A.S.; Rothbard, J.B.; Allen, P.M. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell. 1994, 79, 913-922.
20. Davis M.M.; Boniface, J.J.; Reich,Z.; Lyons, D.; Hampl, J.; Arden, B.; Chien, Y.H. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol., 1998, 16, 523-544.
21. Nicholson, L.B.; Greer, J.M.; Sobel, R.A.; Lees, M.B.; Kuchroo, V.K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity, 1995, 3, 397-405.
22. Nicholson, L.B.; Murtaza, A.; Hafler, B.P.; Sette, A.; Kuchroo, V.K. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. USA, 1997, 94, 9279-9284.
23. Young, D.A.; Lowe, L.D.; Booth, S.S.; Whitters, M.J.; Nicholson, L.; Kuchroo, V.K.; Collins, M. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol., 2000, 164, 3563-3572.
24. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J.A.; McFarland, H.F.; Martin, R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med., 2000, 6, 1167-1175.
25. Kappos, L.; Comi, G.; Panitch, H.; Oger, J.; Antel, J.; Conlon, P.; Steinman, L.; The Altered Peptide Ligand in Relapsing MS Study Group. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med., 2000, 6, 1176-1182.
26. Mantzourani, E.D.; Tselios, T.V.; Goli.. Grdadolnik, S.; Brancale, A.; Platts, J.A.; Matsoukas, J.M.; Mavromoustakos, T.M. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg91, Ala96] MBP87-99. J. Mol. Graph. Mod., 2005, 25, 17-29.
27. Mantzourani, E.D.; Tselios, T.V., Golič Grdadolnik, S; Platts, J.A.; Brancale, A.; Deraos, G.; Matsoukas, J.M.; Mavromoustakos, T.M. Comparison of proposed putative active conformations of myelin basic protein epitope 87-99 linear altered peptide ligands by spectroscopic and modelling studies: the role of positions 91 and 96 in T-cell receptor activation. J. Med. Chem., 2006, 49, 6683-6691.
28. Mantzourani, E.D.; Blokar, K.; Tselios, T.V.; Matsoukas, J.M.; Platts, J.A.; Mavromoustakos T.M.; Grdadolnik S.G. A combined NMR and molecular dynamics simulation study to determine the conformational properties of agonists and antagonists against experimental autoimmune encephalomyelitis. Bioorg. Med. Chem., 2008, 16, 2171-2182.
29. Tselios, T.; Probert, L.; Daliani, I.; Matsoukas, E.; Troganis, A.; Gerothanassis, I.; Mavromoustakos, T.; Moore, G.; Matsoukas, J. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J. Med. Chem., 1999, 42, 1170-1177.
30. Tselios, T.; Daliani, I.; Deraos, S.; Thymianou, S.; Matsoukas, E.; Troganis, A.; Gerothanassis, I.; Mouzaki, A.; Mavromoustakos, T.; Probert, L.; Matsoukas, J. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. Bioorg. Med. Chem. Lett., 2000, 10, 2713-2717.
31. Tselios, T.; Apostolopoulos, V.; Daliani, I.; Deraos, S.; Grdadolnik, S.; Mavromoustakos, T.; Melachrinou, M.; Thymianou, S.; Probert, L.; Mouzaki, A.; Matsoukas, J. Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J. Med. Chem., 2002, 45, 275-283.
32. Tselios, T.; Daliani, I.; Probert, L.; Deraos, S.; Matsoukas, E.; Roy, S.; Pires, J.; Moore, G.; Matsoukas, J. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides. Bioorg. Med. Chem., 2000, 8, 1903-1909.
33. Matsoukas, J.; Apostolopoulos, V.; Kalbacher, H.; Papini, A.M.; Tselios, T.; Chatzantoni, K.; Biagioli, T.; Lolli F.; Deraos, S.; Papathanassopoulos, P.; Troganis, A.; Mantzourani, E.; Mavromoustakos, T.; Mouzaki A. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J. Med. Chem., 2005, 48, 1470-1480.
34. Hahn, M.; Nicholson, M. J.; Pyrdol, J.; Wucherpfennig, K. W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol., 2005, 6, 490-496.
35. Li, Y.; Huang, Y.; Lue, J.; Quandt, J.A.; Martin, R.; Mariuzza, R.A. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J., 2005, 24, 2968-2979.
36. Mantzourani, E.D.; Platts, J.A.; Brancale, A.; Mavromoustakos, T.M.; Tselios, T.V. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response. J. Mol. Graphics Modell., 2007, 26, 471-481.
37. Tysabri™, Biogen Idec, Inc, Cambridge, Massachusetts.
38. Polman, C.H.; O'Connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M.A.; Sandrock, A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354, 899-910.
39. Kappos, L.; Antel, J.; Comi, G.; Montalban, X.; O'Connor, P.; Polman, C.H.; Haas, T.; Korn, A.A.; Karlsson, G.; Radue, E.W.; FTY720 D2201 study group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Eng. J. Med., 2006, 355, 1124-1140.
40. Warrington, A.E.; Bieber, A.J.; Ciric, B.; Pease, L.R.; Van Keulen, V.; Rodriguez, M. A recombinant human IgM promotes myelin repair after a single, very low dose. J. Neurosci. Res., 2007, 85, 967-976.
41. Lincoln, DW.; Lincoln, D.W. In Studies in Gonadotropin-releasing hormone (GnRH): basic physiology; DeGroot. L.J. et al., Ed.; Endrocrinology: Philadelphia, 1997; pp. 142-151.
42. Cook, T.; Sheridan, W.P. Development of GnRH Antagonists for Prostate Cancer: New Approaches to Treatment. Amgen Inc., Thousand Oaks, California, USA. Oncologist, 2000, 5, 162-168.
43. King, J.A.; Millar, R.P. Heterogeneity of vertebrate luteinizing hormone-releasing hormone. Science, 1979, 206, 67-69.
44. King, J.A.; Millar, R.P. Comparative aspects of luteinizing hormone-releasing hormone structure and function in vertebrate phylogeny. Endocrinol., 1980, 106, 707-717.
45. Millar, R.P. GnRHs and GnRH receptors. Anim. Rep. Sci., 2005, 88, 5-28.
46. Millar, R.P. Gonadotropin-releasing hormones and their receptors. In: Fauser BCJM, ed. Reproductive medicine: molecular cellular and genetic fundamentals. Lancaster, UK: Parthenon Publishing; 2002, pp. 199-224.
47. King, J.A.; Millar, R.P. Evolutionary aspects of gonadotropin releasing hormone and its receptor. Cell. Mol. Neurobiol., 1995, 15, 5-23.
48. King, J.A.; Millar, R.P. Coordinated evolution of GnRHs and their receptors. In Studies in: GnRH neurones: gene to behavior. Tokyo: Brain Shuppan; 1997, pp. 51-77.
49. King, J.A.; Millar, R.P. Evolution of gonadotropin-releasing hormone. Trends Endocrinol. Metab., 1992, 3, 339-346.
50. Millar, R.P.; Troskie. B.; Sun, Y.M.; Ott, T.; Wakefield, I.; Myburgh, D.; Pawson, A.; Davidson, J.S.; Katz, A.; Hapgood, J.; Illing, N.; Weinstein, H.; Sealfon, S.C.; Peter, R.E.; Terasawa, E.; King, J.A. Plasticity in the structural and functional evolution of GnRH: a peptide for all seasons. Adv. Compar. Endocr. Proc. XIII International Congress of Comparative Endocrinology, Yokohama, Japan, 1997, pp. 15-27.
51. Sherwood, N.M.; Lovejoy, D.A. Origin of mammalian gonadotropin-releasing hormones. Endocrine. Rev., 1993, 14, 241-254.
52. Jimenez-Linan, M.; Rubin, B.S.; King, J.C. Examination of guinea pig luteinizing-hormone-releasing-hormone gene reveals a unique decapeptide and existence of two transcripts in the brain. Endocrinol., 1997, 138, 423-430.
53. 8]GnRH) in frog brain. Mol. Cell Endocrinol., 2000, 164, 197-204.
54. Okubo, K.; Amano, M.; Yoshiura, Y.; Suetake, H.; Aida, K. A novel form of gonadotropin-releasing hormone in the medaka, Oryzias latipes. Bioch. Bioph. Res. Commun., 2000, 16, 298-303.
55. Adams, B.A.; Tello, J.A.; Erchegyi, J.; Warby, C.; Hong, D.J.; Akinsanya, K.O.; Mackie, G.O.; Vale, W.; Rivier, J.E.; Sherwood, N.M. Six novel gonadotropin-releasing hormones are encoded as triplets on each of two genes in the protochordate, Ciona intestinalis. Endocrinol., 2003, 144, 1907-1919.
56. Iwakoshi, E.; Takuwa-Kuroda, K.; Fujisawa, Y.; Hisada, M.; Ukena, K.; Tsutsui, K.; Minakata, H. Isolation and characterization of a GnRH-like peptide from Octopus vulgaris. Bioch. Bioph. Res. Commun., 2002, 291, 1187-1193.
57. Sealfon, S.C.; Weinstein, H.; Millar, R.P. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocrine Rev., 1997, 18, 180-205.
58. Söderhäll, J.A.; Polymeropoulos, E.E.; Paulini, K.; Günther, E.; Kühne, R. Antagonist and agonist binding models of the humn gonadotropin-releasing hormone receptor. Bioch. Bioph. Res. Commun., 2005, 333, 568-582.
59. Beckers, T.; Bernd, M.; Kutscher, B.; Kuhne, R.; Hoffmann, S.; Reissmann, T. Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. Bioch. Bioph. Res. Commun., 2001, 289, 653-663.
60. Hovelmann, S.; Hoffmann, S.H.; Kuhne, R.; Laak, T.; Reilander, H.; Beckers, T. Impact of aromatic residues within transmembrane helix 6 of the human gonadotropin-releasing hormone receptor upon agonist and antagonist binding, Biochemistry, 2002, 41, 1129-1136.
61. Millar, R.P.; Hu, Z-L.; Pawson, A.J.; Flanagan, C.A.; Morgan, K.; Maudsley, S.R. Gonadotropin-releasing hormone receptors. Endocrine Rev., 2004, 25, 235-275.
62. Stephenson, S.L.; Kenny J.A. The metabolism of neuropeptides. Biochem. J., 1988, 255, 45-51.
63. Gentilucci, L.; Tolomelli, A.; Squassabia, F. Peptides and Peptidomimetics in Medicine, Surgery and Biotechnology. Curr. Med. Chem., 2006, 13, 2449-2466.
64. Sharifi, R.; Knoll, L.D.; Smith J.; Kramolowsky E. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology, 1998, 51, 271-276.
65. Eisenberger, M.A.; O'Dwyer, P.J.; Friedman, M.A. Gondadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J. Clin. Oncol., 1986, 4, 414-424.
66. Garnick, M.B.; Fair, W. Combating prostate cancer. Sci. Amer., 1998, 279, 74-83.
67. Loffett, A. Peptides as Drugs: Is There a Market? J. Pept. Sci., 2002, 8, 1-7.
68. Garnick, M.B.; Gittelman, M.; Steidle, C. Abarelix (PPI-149), a novel and potent GnRH antagonist, induces a rapid and profound prostate gland volume reduction (PGVR) and androgen suppression before brachytherapy (BT) or radiation therapy (XRT). J. Urol., 1998, 159, 220.
69. Leaños-Miranda, A.; Ulloa-Aguirre, A.; Cervini, L.A.; Janovick, J.A.; ivier, J.; Conn, M. Identification of new gonadotrophin-releasing hormone partial agonists. J. Endocrin., 2006, 189, 509-517.
70. Samant, M.P.; Hong, D.J.; Croston, G.; Rivier, C.; Rivier, J. Novel Gonadotropin-Releasing Hormone Antagonists with Substitutions at Position 5*. Inc. Biopolymers, 2005, 80, 386-391.
71. Jiang, G.; Stalewski, J.; Galyean, R.; Dykert, J.; Schteingart, C.; Broqua, P.; Aebi, A.; Aubert, M.L.; Semple, G.; Robson, P.; Akinsanya, K.; Haigh, R.; Riviere, P.; Trojnar, J.; Junien, J.L.; Rivier, J.; GnRH Antagonists: A New Generation of Long Acting Analogues Incorporating p-Ureido-phenylalanines at Positions 5 and 6. J. Med. Chem., 2001, 44, 453-467.
72. Samant, M.P.; Miller, C.; Hong, D.J.; Koerber, S.C.; Croston, G.; Rivier, C.L.; Rivier, J.E. Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine. J. Pept. Res., 2005, 65, 284-291.
73. Samant, M.P.; Gulyas, J.; Hong, D.J.; Croston, G.; Rivier, C.; Rivier, Synthesis, in vivo and in vitro biological activity of novel azaline B analogs. J. Chem. Let., 2005, 15, 2894-2897.
74. Samant, M.P.; White, R.; Hong, D.J.; Croston, G.; Conn, P.M.; Janovick, J.A.; Rivier J. Structure-Activity Relationship Studies of Gonadotropin-Releasing Hormone Antagonists Containing S-Aryl/Alkyl Norcysteines and Their Oxidized Derivatives. J. Med. Chem., 2007, 50, 2067-2077.
75. Samant, M.P.; Rivier, J.E. Norcystine, a New Tool for the Study of the Structure-Activity Relationship of Peptides. Org. Let., 2006, 11, 2361-2364.
76. Koerber, S.C.; Rizo, J.; Struthers, R.S.; Rivier, J.E. Consensus Bioactive Conformation of Cyclic GnRH Antagonists Defined by NMR and Molecular Modeling. J. Med. Chem., 2000, 43, 819-828.
77. Rivier, J.E.; Porter, J.; Cervini, L.A.; Lahrichi, S.L.; Kirby, D.A.; Struthers, R.S.; Koerber, S.C.; Rivier, C.L. Design of Monocyclic (1-3) and Dicyclic (1-3/4-10) Gonadotropin Releasing Hormone (GnRH) Antagonists. J. Med. Chem., 2000, 43, 797-806.
78. Rivier, J.E.; Struthers, R.S.; Porter, J.; Lahrichi, S.L.; Jiang, G; Cervini, L.A.; Ibea, M.; Kirby, D.A.; Koerber, S.C.; Rivier, C.L. Design of Potent Dicyclic (4-10/5-8) Gonadotropin Releasing Hormone (GnRH) Antagonists. J. Med. Chem., 2000, 43, 784-796.
79. Rivier, J.E.; Jiang, G.; Struthers, R.S.; Koerber, S.C.; Porter, J.; Cervini, L.A.; Kirby, D.A.; Craig, A.G.; Rivier, C.L. Design of Potent Dicyclic (1-5/4-10) Gonadotropin Releasing Hormone (GnRH) Antagonists. J. Med. Chem., 2000, 43, 807-818.
80. Broqua, P.; Riviere, P.J.; Conn, P.M.; Rivier, J.E.; Aubert, M.L.; Junien, J.L. Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix. J. Pharmacol. Exp. Ther., 2002, 301, 95-102.
81. Samant, M.P.; Gulyas, J.; Hong, D.J.; Croston, G.; Rivier, C.; Rivier, J. Iterative Approach to the Discovery of Novel Degarelix Analogues: Substitutions at Positions 3, 7, and 8. Part II. J. Med. Chem., 2005, 48, 4851-4860.
82. Samant, M.P.; Hong, D.J.; Croston, G.; Rivier, C.; Rivier, J. Novel Analogues of Degarelix Incorporating Hydroxy-, Methoxy-, and Pegylated-Urea Moieties at Positions 3, 5, 6 and the N-Terminus Part III. J. Med. Chem., 2006, 49, 3536-3543.
83. Ratcliffe, K.E.; Fraser, H.M.; Sellar, R.; Rivier, J.; Millar, R.P. Bifunctional Gonadotropin-Releasing Hormone Antagonist-Progesterone Analogs with Increased Efficacy and Duration of Action. Endocrinol., 2006, 147, 571-579.
84. Gangatirkar, P.; Gangadharan, S.; Narendranath, A.; Nagpal, S.; Salunke, D.M.; Karande, A.A.; Monoclonal Antibodies to Gonadotropin-Releasing Hormone (GnRH) Inhibit Binding of the Hormone to its Receptor. Endocrinol., 2002, 21, 281-286.
85. Timmermans, P.B.M.W.M.; Wexler, R.R. Medicinal Chemisty of the Renin- Angiotensin System, 1994.
86. Hoit, B.D.; Shao, Y.; Kinoshita, A.; Gabel, M.; Husain, A.; Walsh, R. A. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J. Clin. Invest., 1995, 95, 1519-1527.
87. Shiota, N.; Fukamizu, A.; Takai, S.; Okunishi, H.; Murakami, K.; Miyazaki, M.: Shiota N, Fukamizu A, Takai S, Okunishi H, Murakami K, Miyazaki M. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J. Hypertens., 1997, 15, 431-440.
88. Johnston, C.I.; Risvanis, J.: Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues. Am. J. Herpertens., 1997, 10, 306-310.
89. Ondetti, M.A.; Rubin, B.; Cushman, D.W. Design of specific inhibitors of angiotensin converting enzyme. New class of orally active antihypertensive agents. Science, 1977, 196, 441-444.
90. Patchett, A.A.; Harris, E.; Tristram, E.W.; Wyvratt, M.J.; Wu, M.T.; Taub, D.; Peterson, E.R.; Ikeler, T.J.; Broeke, J.; Payne, L.G.; Ondeyka, D.L.; Thorsett, E.D.; Greenlee, W.J.; Lohr, N.S.; Hoffsommer, R.D.; Joshua, H.; Ruyle, W.V.; Rothrock, J.W.; Aster, S.D.; Maycock, A.L.; Robinson, F.M.; Hirschmann, R.; Sweet, C.S.; Ulm, E.H.; Gross, D.M.; Vassil, T.C.; Stone, C.A. A new class of angiotensin-converting-enzyme inhibitors. Nature, 1980, 288, 280-283.
91. Bussien, J.P.; Waeber, B.; Nussberger, J.; Gomez, H.J.; Brunner, H.R. Once-daily lisinopril in hypertensive patients: effect on blood pressure and the renin-angiotensin system. Curr. Therap. Res., 1985, 37, 342-351.
92. Hou, F.; Zhang, X.; Zhang, G.; Xie, D.; Chen, P.; Zhang, W.; Jiang, J.; Liang, M.; Wang, G.; Liu, Z.; Geng, R. N. Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency. Engl. J. Med., 2006, 354, 131-140.
93. Mathew, J.; Sleight, P.; Lonn, E.; Johnstone, D.; Pogue, J.; Yi, Q.; Bosch, J.; Sussex, B.; Probstfield, J.; Yusuf, S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation., 2001, 104, 1615-1621.
94. Blankle, C.J.; Cohe, D.M.; Essenbur, A.D.; Flemin, R.W.; Hinkle, J.M.; Hoefl, M.L.; Holme, A.; Klutchk, S.; Nordi, I.; Werne, A.E. Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J. Med. Chem., 1986, 29, 1953-1961.
95. Lechat, P.; Granham, S.P.; Desche, P.; Bounhoure, J.P. Efficacy and acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Am. Heart J., 1993, 126, 798-806.
96. Krapcho, J.; Turk, C.; Cushman, D.W.; Powell, J.R.; Deforrest, J.M.; Spitzmiller, R.; Karanewsky, D.; Duggan, M.; Rovnyak, G. and et al. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted pralines. J. Med. Chem. 1988, 31, 1148-1160.
97. Skeggs, L.T. Jr.; Kahn, J.R.; Lentz, K.; Shumway, N.P. The preparation, purification, and amino acid sequence of a polypeptide rennin substrate. J. Exper. Med., 1957, 106, 439-453.
98. Doggrell, S.A.; Wanstall, J.C. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc. Res., 2004, 61, 653-662.
99. Ohler, E. A.; Wakerlin, G. E. Amines in Experimental Hypertensions. Circulation, 1953, 2, 122-128.
100. Wood, J.M.; Cumin, F.; Maibaum, J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther., 1994, 61, 325-344.
101. Wood, J.M.; Criscione, L.; de Gasparo, M.; Bühlmayer, P.; Rüeger, H.; Stanton, J.L.; Jupp, R.A.; Kay, J. CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. J. Cardiovasc. Pharmacol., 1989, 14, 221-226.
102. Lefevre, G.; Duval, M.; Poncin, A. Direct Micro-Radioimmunoassay Of The New Renin Inhibitor. J. Immunoassay, 2000, 21, 65-84.
103. Staessen, J.A.; Li, Y.; Richart, T. Oral renin inhibitors. Lancet, 2006, 368, 1449-1456.
104. Matsumura, Y.; Hasser, E.M.; Bishop, V.S. Central affects of angiotensin II on baroreflex regulation in conscious rabbits. Am. J. Physiol. Regul. Integr. Comp. Physiol., 1989, 256, R694-700.
105. Smeby, R.R.; Arakawa, K.; Bumpus, F.M.; Marsh, M.M. A proposed conformation of isoleucyl-5-angiotensin II. Biochim. Biophys. Acta, 1962, 58, 550-557.
106. Glancer, C.S.; Wagner, H.; Glancer, E. M.; Sevy, R.W. A proposed structure and active site of angiotensin. Curr. Mod. Biol., 1970, 3, 221-224.
107. Printz, M.P.; Williams, H.P.; Craig, L.C. Evidence for the presence of hydrogen-bonded secondary structure in angiotensin II in aqueous solution. Proc. Natl. Acad. Sci., 1972, 69, 378-382.
108. Fermandjian, S.; Fromageot, P.; Tistchenko, A.M.; Leicknam, J.P.; Lutz, M. Angiotensin II conformations. Infrared and raman studies. Eur. J. Bioch., 1972, 28, 174-182.
109. Matsoukas, J.M.; Polevaya, L.; Ancans, J.; Mavromoustakos, T.; Kolocouris, A.; Roumelioti, P.; Vlahakos, D.V.; Yamdagni, R.; Wu Q.; Moore, G.J. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II. Bioorg. Med. Chem., 2000, 8, 1-10.
110. Lin, S.Y.; Goodfriend, T.L. Angiotensin receptors. Am. J. Physiol., 1970, 218, 1319-1328.
111. Underwood, D.J.; Strader, C.D.; Rivero R, Patchett AA, Greenlee W, Prendergast, K. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol., 1994, 4, 211-221.
112. Hoflack, J.; Trumppkallmeyer, S.; Hibert. M. Re-evaluation of bacteriorhodopsin as a model for G protein-coupled receptors. Trends Pharmacol. Sci., 1994, 15, 7-9.
113. Strader, C.; Fong, T.; Tota, M.; Underwood, D. Dixon, R. Structure and function of G protein coupled receptors. Annu. Rev. Biochem., 1994, 63, 101-132.
114. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Science, 2000, 289, 739-745.
115. Li, J.; Edwards, P.C.; Burghammer, M.; Villa, C.; Schertler, G.F. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol., 2004, 343, 1409.
116. Baldwin, J. The probable arrangement of the helices in G protein-coupled receptors. EMBO J., 1993, 12, 1693-1703.
117. Noda, K.; Feng, Y.H.; Liu, X.P.; Saad, Y.; Husain, A.; Karnik, S.S. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry, 1996, 35, 16435-16442.
118. Hjorth, S.A.; Schambye, H.T.; Greenlee, W.J.; Schwartz, T.W. Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J. Biol. Chem., 1994, 269, 30953-30959.
119. 111. Biochemistry, 1998, 37, 15791-15798.
120. Han, H.M.; Shimuta, S.I.; Kanashiro, C.A.; Oliveira, L.; Han, S.W.; Paiva, A.C. Residues Val254, His256, Phe259 of the angiotensin II AT1 receptor are not involved in ligand binding but participate in signal transduction. Mol. Endocrinol., 1998, 12, 810-814.
121. 256 of AT Receptor in Agonist Activation. J. Biol. Chem. 1995, 270, 28511-28514.
122. 281 of AT Receptor Is Essential for Full Agonism. J. Biol. Chem., 1995, 270, 12846-12850.
123. Karnik, S.S.; Husain, A.; Graham, R.M. Molecular determinants of peptide and non-peptide binding to the AT1 receptor. Clin. Exp. Pharmacol. Physiol. Suppl., 1996, 3, S58-66.
124. 1). J. Biol. Chem. 1995, 270, 14024-14030.
125. 1]-angiotensin II. Regul. Pept., 2004, 119, 183-188.
126. 1A receptor. Br. J. Pharmacol., 2000, 130, 1263-1268.
127. Case, D.B.; Wallace, J.M.; Laragh, J.H. Comparison between saralasin and converting enzyme inhibitor in hypertensive disease. Kidney. Int., 1979, 15, S107-144.
128. Turker, R.K.; Page, I.H.; Bumpus, F.M. Antagonists of angiotensin II, in Angiotensin (Handbook of Experimental Pharmacology), Springer-Verlag: New York, 1974.
129. Furukawa, Y.; Kishimoto, S.; Nishikawa, K. US Pat. 4340598, 1982.
130. Duncia, J.V.; Chiu, A.T.; Carini, D.J.; Gregory, G.B.; Johnson, A.L.; Price Jr., W.A.; Wells, G.J.; Wong, P.C.; Calabrese, J.C.; Timmermans, P.B.M.W.M. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J. Med. Chem., 1990, 33, 1312-1329.
131. Weinstock, J.; Keenan, R.M.; Samanen, J.; Hempel, J.; Finkelstein, J.A.; Franz, R.G.; Gaitanopoulos, D.E.; Girard, G.R.; Gleason, J.G.; Hill, D.T.; Morgan, T.M.; Peishoff, C.E.; Aiyar, N.; Brooks, D.P.; Frederickson, T.A.; Ohlstein, E.H.; A.; Hartupee, D.; Oshiro, G.; Colatsky, T.J. FASEB J., 1994, 8, A5.Ruffolo, R.R.; Stack, E.J.; Sulpizio, A.C.; Weidley, E.F.; Edwards, R.M. 1-(Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J. Med. Chem., 1991, 34, 1514-1517.
132. Shibouta, Y.; Inada, Y.; Ojima, M.; Wada, T.; Noda, M.; Sanada, T.; Kubo, K.; Nishikawa, K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist. J. Pharm. Exp. Ther., 1993, 266, 114-120.
133. Christophe, B.; Libon, R.; Cazaubon, C.; Nisato, D.; Manning, A.; Chatelain, P. Effect of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Eur. J. Pharm., 1995, 281, 161-171.
134. Norwood, D.; Branch III, E.; Smith, B.; Honeywell, M. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast, 2002, 27, 611-618.
135. 1-selective nonpeptidic angiotensin II (A II) receptor antagonist. FASEB J., 1994, 8, A5.
136. Ries, U.J.; Mihm, G.; Narr, B.; Hasselbach, K.M.; Wittneben, H.; Entzeroth, M.; Van Meel, J.C.A.; Wienen, W.; Hauel, N.H. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J. Med. Chem. 1993, 36, 4040-4051.
137. Buhlmayer, P.; Furet, P.; Criscione, L.; de Gasparo, M.; Whitebread, S.; Schmidlin, T.; Lattmann, R.; Wood, J. Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series. Bioorg. & Med. Chem. Lett., 1993, 4, 29-34.
138. Judd, D.B.; Cardwell, K.S.; Panchal, T.A.; Jack, T.I.; Pass, M.; Hubbard, T.; Dean, A.W.; Butt, A.U.; Hobson, J.E.; Heron, N.M.; Watson, S.P.; Currie, G.S.; Middlemiss, D.; Allen, D.G.; Aston, N.M.; Paton, J.M.S.; Drew, G.M.; Hilditch, A.; Gallacher, D.; Bayliss, M.K.; Donnelly, M.C. Benzofuran based non-peptide antagonists of angiotensin II related to GR117289. IV: Imidazopyridinyl-benzofurans. Bioorg. & Med. Chem. Lett., 1994, 4, 725-728.
139. Neutel, J.M.; Smith, D.H.G. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv. Therap., 1998, 15, 206-217.
140. Stasch, J.P.; Knorr, A.; Hirth-Dietrich, C.; Krämer, T.; Hübsch, W.; Sander, E.; Frobel, K.; Kazda, S. Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats and stroke-prone spontaneously hypertensive rats. Naunyn-Schmiedeberg's Arch. Pharmacol., 1996, 353, R69.
141. Tamura, K.; Okuhira, M.; Amano, H.; Inokuma, K.I.; Hirata, T.; Mikoshiba, I.; Hashimoto, K. Pharmacologic Profiles of KRH-594, a Novel Nonpeptide Angiotensin II-Receptor Antagonist. J. Cardiovasc. Pharm., 1997, 30, 607-615.
142. Yanagisawa, T.; Ueyama, N.; Kawai, T.; Sonegawa, M.; Baba, H.; Mochizuki, S.; Kozakai, K.; Tomiyama, T. 4,5,6,7-Tetrahdryo-8-oxo-cycloheptimidazoles: a new class of potent non-peptide angiiotensin II receptor antagonists. Bioorg. & Med. Chem. Lett., 1993, 3, 1559-1564.
143. Aulakh, G.K.; Sodhi, R.K.; Singh, M. An update on non-peptide angiotensin receptor antagonists and related. RAAS modulators. Life Sc., 2007, 81, 615-639.
144. Ambühl, P.M.; Tissot, A.C.; Fulurija, A.; Maurer, P.; Nussberger, J.; Sabat, R.; Nief, V.; Schellekens, C.; Sladko, K.; Roubicek, K.; Pfister, T.; Rettenbacher, M.; Volk, H.D.; Wagner, F.; Müller, P.; Jennings, G.T.; Bachmann, M.F. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertens., 2007, 25, 63-72.
145. Tissot, A.C.; Maurer, P.; Nussberger, J.; Sabat, R.; Pfister, T.; Ignatenko, S.; Volk, H.D.; Stocker, H.; Müller, P.; Jennings, G.T.; Wagner, F.; Bachmann, M.F. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet, 2008, 371, 821-827.